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Relevance Statement 
 
People with severe mental illness (SMI) are more likely than the general population to use novel 
psychoactive substances (NPS). Unlike the effects of illicit drugs such as cannabis, the effects of NPS 
on people with SMI are unknown. In order to provide the best support and care to people with SMI, 
mental health nurses need to understand the potential effects of NPS and the circumstances of their 
use. This systematic review aimed to synthesise the state of knowledge about the effects of NPS on 
people with SMI.  
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A systematic review of the effects of novel psychoactive substances “legal 
highs” on people with severe mental illness 
 
Abstract 
 
Introduction: Novel psychoactive substances (NPS) are synthetic substances that have been 
developed to produce altered states of consciousness and perceptions. People with severe mental 
illness (SMI) are more likely to use NPS than people without mental illness, but the short and long-
term effects of NPS are largely unknown. 
Method: We systematically reviewed the literature about the effects of NPS on people with SMI.  
Results: We included 12 case reports, 1 cross-sectional survey and 1 qualitative study. Participants 
included mostly males aged between 20 and 35 years. A variety of NPS were used, including synthetic 
cathinones and herbs such as salvia. The most commonly reported effects of NPS were psychotic 
symptoms (in some cases novel in form and content to the patients’ usual symptoms) and significant 
changes in behaviour, including agitation, aggression and violence. Patients’ vital signs; blood 
pressure, pulse rate and temperature were also commonly affected.  
Conclusion: NPS potentially have serious effects on people with severe mental illness but our findings 
have limited generalisability due to a reliance on case studies. There is a paucity of evidence about the 
long-term effects of these substances. Further research is required to provide a better understanding 
about how different NPS affect patients’ mental and physical health.  
 
PROSPERO Identifier: CRD42015026944 
 
Keywords: legal highs, novel psychoactive substances, psychotic disorders, severe mental illness, 
schizophrenia, systematic review 
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Accessible summary 
What is known on the subject? 
- Novel psychoactive substances (NPS) include synthetic drugs mimicking the effects of illicit 
drugs, e.g. synthetic cannabinoids, and herbs such as salvia divinorum. NPS are substances 
that can trigger hallucinations and other effects altering the mind, and are currently 
uncontrolled by the United Nations’ 1961 Narcotic Drugs/1971 Psychotropic Substances 
Conventions. 
- NPS affect brain chemistry that induces the psychoactive effects, such as hallucinations and 
feeling ‘high’. It is unknown what effects such drugs have on people with severe mental 
illness (i.e. psychotic illnesses). 
 
What this paper adds to existing knowledge? 
- Our review demonstrates that little is known about the effects of various NPS on people with 
severe mental illness. Almost nothing is known about the long-term consequences of NPS use 
on the mental and physical health of SMI patients. 
- Patients may lack understanding that NPS are psychoactive drugs that can impact on their 
mental and physical wellbeing. 
 
What are the implications for practice? 
- Some patients might be reluctant or do not think it is relevant to disclose NPS use. Commonly 
used illicit drug-screening is unlikely to detect the presence of NPS, therefore health and 
mental health professionals should directly enquire about NPS and actively encourage patients 
with severe mental illness to disclose any substance use.  
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Background 
People with severe mental illness (SMI) such as schizophrenia and bipolar disorder are at increased 
risk of suffering comorbid conditions including substance misuse (Merikangas et al 2008). For 
example, a study based on Danish national data showed that between 28-35% of people with psychotic 
disorders also have a coexisting substance use disorder (Toftdahl et al 2015). At the same time, 
substance misuse, especially cannabis use, is a known risk factor for developing psychosis (Arseneault 
et al 2002). There is also evidence that people with a dual diagnosis (substance use and SMI) have 
worse clinical outcomes in terms of symptom control, adherence to treatment and rates of violence and 
aggression (Soyka, 2000).  
 
In recent years, new drugs and drug substitutes have emerged, possibly in response to the increased 
control of illicit drugs (EMCDDA, 2014). The use of so called ‘legal highs’ or novel psychoactive 
substances (NPS) is becoming increasingly common and NPS have been tried by at least 5% of young 
people aged 15-24 in the EU (Flash Eurobarometer, 2011). There is some evidence of considerable 
variation in the prevalence of use between countries, for example 1% of young people in Italy and 
16% in Ireland are reported to have tried NSPs (Flash Eurobarometer, 2011).  
 
The UK government has introduced the Novel Psychoactive Substances 2015 bill in an attempt to ban 
all new and future substances with psychoactive effects intended for humans (excluding nicotine, 
caffeine, alcohol, food and medicines) in an attempt to keep up to date with new and emerging 
substances.  
 
NPS are defined as narcotic or psychotropic drugs that are not currently controlled by the United 
Nations’ 1961 Narcotic Drugs/1971 Psychotropic Substances Conventions, but which might pose a 
public health threat comparable to that posed by substances listed in these conventions (EMCDDA, 
2006). Examples include synthetic cannabimimetics containing molecules that bind to cannabinoid 
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receptors, synthetic cathinones that are similar to amphetamines such as “bath salts” or 
methylenedioxypyrovalerone (MDPV) , new drugs mimicking the effects of MDMA (“Ecstasy”) and 
other substances including herbs like salvia divinorum, which can cause state of delirium and 
hallucinations (Schifano et al, 2015). Such substances are currently uncontrolled but hundreds of drugs 
with variable ingredients and untested effects/risks are available for purchase on the internet (Nelson 
et al, 2014). Within the general population, intoxication with novel psychoactive substances can pose 
significant health and mental health risks to their users, including but not limited to hallucinations, 
agitation, tachycardia, hypertension, vomiting, seizures, stroke, rhabdomyosis (uncontrolled 
breakdown of muscle), kidney injuries and death (Schifano et al, 2015). The effects of NPS on people 
with existing severe mental illness are largely unknown. 
 
The use of NPS  appears to be significantly more common in people with psychiatric illnesses 
compared to healthy people (Martinotti et al 2014). It is therefore imperative to understand what 
effects NPS have on health and mental health, and specifically on people with co-existing mental 
illnesses. 
 
Dopamine is a neurotransmitter with an established role in psychosis (Howes and Kapur, 2009). 
Studies involving PET scans of acutely psychotic patients show increased presynaptic levels of 
dopamine (Lindstrom et al, 1999). Dopamine is a neurotransmitter involved in controlling behaviours 
and thought processes (Cools, 2008). In a review of the literature, Schifano et al (2015) reported that 
dopamine function is disturbed when certain NPS (e.g. synthetic cathinones, synthetic cocaine 
substitutes and some novel stimulants such as methiopropamine) are used, triggering their 
psychoactive effects. It might be hypothesised that NPS use in people with severe mental illness could 
have stronger and more severe effects. However, the link between psychosis and NPS has not been 
examined. While various mental health complications have been described in people who have taken 
NPS (Schifano et al, 2015), to the best of our knowledge there has not been a systematic review that 
has examined the effects of NPS on patients with severe mental illness.  
 
Review question 
The aim of this systematic review is to explore the effects of novel psychoactive substances (NPS) on 
the mental and physical health of people with SMI. 
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Methodology 
We have followed the PRISMA guideline for reporting systematic reviews (Moher et al, 2009). The 
protocol is registered on Prospero International Prospective Register of Systematic Reviews 
(http://www.crd.york.ac.uk/PROSPERO/:2015 registration number:  CRD42015026944 
 
1.1 Search strategy 
We used a broad sensitive search strategy to identify the relevant studies from the following electronic 
databases:  
 EMBASE/OVID (1947-2015). 
 MEDLINE/OVID (1961-2015); 
 Cumulative Index to Nursing and Allied Health (CINAHL with Full Text) (1904-2015); 
 The Cochrane Library (1900-2015); 
 Scopus  
 Pubmed 
 
We also reviewed the reference lists of important articles in order to identify further potentially 
relevant papers, and we included papers identified serendipitously. 
 
Our search string consisted of two main concepts. We searched the following keywords or key concept 
terms (as appropriate) related to novel psychoactive substances: “new psychoactive substances” OR 
“novel psychoactive substances” OR “legal highs” OR “designer drugs” OR “research chemicals” OR 
“smart drugs” OR “emerging drugs of abuse”. They were subsequently combined using ‘AND’ with 
the search terms related to the concept of severe mental illness: “schizophrenia” OR “manic depressive 
psychosis” OR “bipolar disorder” OR “psychosis” OR “psychotic disorders” OR “schizoaffective 
psychosis” OR “mania” OR “mixed mania and depression” OR “bipolar mania” OR “bipolar affective 
disorder” OR “depressive psychosis” OR “affective psychosis”. The search strategy was adapted 
accordingly for each database. 
 
1.2 Inclusion criteria 
This review is concerned with adults (aged 18 years or over) with a diagnosis of SMI and a history of 
NPS use. We included studies using any research design, reporting on how exposure to NPS affects 
mental and physical health of people with a current diagnosis of SMI. We included studies published 
in English with no restriction of context (i.e. any country, inpatients or outpatients), published in peer-
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reviewed professional journals (including conference proceedings) before or electronically available in 
October 2015. 
 
Participants 
Studies were included if the participant(s) are described in the publication as being diagnosed with a 
SMI. Severe mental illness is defined as a documented diagnosis of schizophrenia or 
delusional/psychotic illness (ICD 10 F20.9 & F22 or DSM-equivalent) or bipolar disorder (ICD F31 or 
DSM-equivalent). The SMI-inclusive diagnosis was established by either a gold-standard structured 
clinical interview for establishing a DSM-IV/DSM-V or ICD-10 diagnosis (e.g. Structured Clinical 
Interview for DSM-IV/DSM-V), or made by a mental health professional and documented in the 
medical record. 
 
Exposure 
We included studies where participants were reported to have used novel psychoactive substances, 
which are narcotic or psychotropic drugs that are not currently controlled by the United Nations’ 1961 
Narcotic Drugs/ 1971 Psychotropic Substances Conventions but might pose a public health threat, as 
defined by the European Monitoring Centre for Drugs and Drug Addiction (EMCCDA, 2006). No 
comparator was defined for this review. 
 
Outcomes 
The primary outcome was change in psychiatric symptomatology of an existing SMI diagnosis in 
relation to recent use of NPS. Secondary outcomes were any other health-related effects caused by the 
use of NPS in people with SMI. 
 
1.3 Study selection and data extraction 
Articles identified in the literature searches were exported into reference management software 
(Endnote™). Duplicate records were excluded (using Endnote and manually) and the titles and 
abstracts of the individual articles were screened for eligibility based on inclusion criteria. We 
developed a data extraction tool for this review and piloted it on a sample of studies to check its utility. 
The relevant information about each study was recorded by two reviewers independently (AI and DB). 
We recorded the study characteristics, information about the study design and methodology, 
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participant characteristics (including the demographic and clinical characteristics) and the outcomes of 
the NPS exposure (i.e. the effects of NPS on health and mental health of the participants). 
 
1.4 Risk of bias and quality assessment 
We anticipated inclusion of studies using various designs. Their risk of bias (ROB) and 
methodological quality were therefore assessed using different validated ROB assessment tools, as 
appropriate. Qualitative research articles were assessed using a Critical Appraisal Skills Programme 
(CASP) tool (CASPa, 2014), case studies were assessed using a Newcastle-Ottawa quality assessment 
scale for case control studies (Wells et al, 2013) and other observational studies were assessed using a 
CASP tool for cohort studies (CASP, 2014b). The assessment of the risk of bias or quality of studies 
was not used to decide eligibility or inclusion of the relevant papers. Instead, the assessed risk of 
bias/quality will be reported to inform the interpretation of the findings. 
 
1.5 Data synthesis 
Information gathered from the included studies was synthesised according to the main principles of 
narrative synthesis (Popay, 2006).  
 
Results 
Figure 1 shows the flow of the articles through the review process. In the electronic database search 
and through other sources, we identified a total of 550 papers. After removing duplicates and non-
English papers, we screened 367 titles and abstracts and excluded 234 records. We assessed 133 
articles for eligibility, excluding a total of 119 mostly because their focus was not on SMI (n=67) were 
reviews (n=8) or commentary articles (n=15). One paper was excluded as we were unable to retrieve a 
full text copy of the manuscript from the British Library. We included 12 full studies and 2 conference 
abstracts that met our inclusion criteria. Included studies were published between 2011 and 2015. 
 
[Insert figure 1] 
 
Study description 
Thirteen of the 14 studies included in this review were non-comparative reports. Specifically, we 
identified 10 single case reports, 2 case-series and 1 study involving qualitative interviews with NPS 
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users about their experiences with the substances. One study (Lally et al, 2013), was an explorative 
questionnaire study comparing the prevalence of using ‘head shops’ to buy NPS by people with 
mental illness and people without. A total of 7 studies were conducted in Europe (3 in UK, 3 in 
Ireland, 1 in Slovenia), 3 in the USA, 1 in India and 2 studies were in other countries (unreported). 
Four studies were conducted in inpatient or acute psychiatric clinics (Anderson et al, 2015 and Smith 
et al, 2013 in the UK; Celofiga et al, 2014 in Slovenia and Tully et al, 2011 in Ireland), 2 in outpatient 
clinics (McClean et al, 2012 in the UK; Khanra et al, 2015 in India) , 6 in emergency departments 
within hospitals (Boucher et al, 2015 and Marques et al, 2013 in unreported countries; Falgiani et al, 
2012; Imam et al, 2013; Thornton et al, 2012 in the USA and Fröhlich et al, 2011 in Ireland), 1 in a 
forensic rehabilitation centre, New Zealand (Every-Palmer, 2011) and 1 in Ireland in a day hospital 
(Lally et al, 2013). 
 
Risk of bias and quality of the studies 
The risk of bias and quality of the 12 case studies (including the conference abstract reports) were 
assessed using the Newcastle-Ottawa quality assessment scale for case control studies, due to a lack of 
appropriate assessment tools for non-comparative case reports. Since the studies did not involve 
control participants, we determined that three out of the eight questions in the tool were applicable for 
case reports. Case reports are subject of relatively high inherent risk of bias due to involving a small 
number of participants who are often selected conveniently, without an opportunity to compare the 
identified effects with a control group. The case reports included between one and four participants, 
making their samples unrepresentative of any given population. In addition to the high inherent risk of 
bias, all but two studies included in this review reported patient’s diagnosis but do not indicate how it 
was obtained. No study reported the number of other potential cases within their institution in any 
given time period. Patients’ exposure to NPS was in most cases determined by self-report, providing 
further opportunity for bias. 
 
We also included one qualitative study (Every-Palmer, 2011) and one cross-sectional survey (Lally et 
al, 2013). Their risk of bias was assessed using the Critical Appraisal Skills Programme (CASP) tool 
for qualitative and cohort studies, respectively. Lally, et al (2013) was deemed to have a risk of 
sampling bias due to recruiting all presentations rather than only new cases within the eight local 
hospitals. The risk of recall bias was also present due to reliance on patients’ self-reports over the past 
12 months. The authors identified—but did not measure and/or take account of—confounding factors 
such as alcohol use, employment and socioeconomic status, which again increased the study’s risk of 
bias. The qualitative study (Every-Palmer, 2011) also had a relatively high risk of bias. The authors 
provided scant details of the study. The study aims were not clearly stated, making it difficult to 
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determine how appropriate the research design was. Not enough detail was provided regarding the 
recruitment process, exploration of the relationship between the researcher and participants during data 
collection, and how the thematic analysis was undertaken. 
 
Participants 
Table 1 shows the key characteristics of the participants involved in the studies included in this 
review. The case studies involved a total of 19 participants, of whom 17 had prior SMI. This is 
because one of the case series described 2 participants with a history of SMI and two people without 
mental illness, we only included the two participants with SMI. Participants in the case studies had 
diagnoses of schizophrenia (n=10), bipolar disorder (n=4) and in one study the authors mentioned a 
patient had a psychiatric history without providing further details of their diagnosis (Thornton et al, 
2012). The majority of the patients in the studies were male (n=14; 82%) and the mean age was 31 
years (SD=7). 
The qualitative study (Every-Palmer, 2011) included 21 participants. Of which, 15 were eligible for 
this review. All were male with mean age of 34 years (SD=8). The study using questionnaires (Lally et 
al, 2013) involved 608 participants, of whom 135 had psychotic disorders. Of the 135 patients, 23 
(17%) had purchased NPS in specialised drug shops called ‘head shops’. Further demographic 
information about the sample in this survey was only provided for the whole group of 608 participants. 
 
[Insert table 1] 
 
Exposure: NPS used in the included studies 
Table 2 shows that most of the case study participants had used substances described as “bath salts” 
without further specification (n=5), 4 had used same type of synthetic cannabinoid called (1-(5-
fluoropentyl)-3-(1-naphthoyl) indole (AM-2201) and 6 had used other types of substances. The others 
included herbs Datura stramonium, Salvia divinorum, a substance called ‘el blanco’, an amphetamine 
type stimulant containing a mixture of Methylenedioxypyrovalerone (MDPV) and flephedrone, and 
benzylpiperazine (BZP). All of the questionnaire study participants had used the same type of 
synthetic cannabinoid, called JWH-018 (n=15). Participants in the survey study (Lally et al, 2013) had 
used a number of different substances that included synthetic cannabinoids (e.g. ‘Spice’ and ‘Smoke 
XXX’), benzylpiperazine and piperazine derivates mephedrone, methcathinone and methylone among 
others. 
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[Insert table 2] 
 
1.6 Outcomes: Health and mental health effects of NPS 
Table 3 summarises the mental and physical effects of NPS reported in the included studies. In all of 
the case studies, the authors reported that the NPS taken had a significant impact on the patients’ 
mental state. 
 
[Insert table 3] 
 
Short term effects 
Out of a total of 17 cases, 15 reported a range of psychotic symptoms after taking NPS. Two were 
reported as being unconscious as a result of NPS use on admission to hospital intensive care 
unit/emergency department (Boucher et al, 2015; Falgiani et al, 2012). The psychotic symptoms most 
commonly reported included delusions, hallucinations (including haptic, auditory, visual and tactile), 
severe thought disorder (including incoherent speech and tangential thought processes) and altered 
mental status (specific details not provided). Authors of a study involving 4 already hospitalised 
patients observed that all patients demonstrated new psychotic symptoms with no exacerbation of their 
previously known symptoms (Celofiga et al, 2014). In the qualitative study (Every-Palmer, 2011), all 
patients reported the onset of psychotic symptoms following the use of NPS. Psychotic symptoms 
were also identified by users as an effect of NPS in a survey study (Lally et al, 2013). Participants in 
the qualitative study appeared to perceive NPS as less harmful or ‘natural’ substances, which ‘make 
you high’ in a faster and safer way, compared to illicit drugs (Every-Palmer, 2011). 
 
Patients’ behaviour after the use of NPS was also severely affected. In 9 of the 17 cases, bizarre or 
chaotic behaviour was observed, which included repetitive movements, crawling on the floor or 
running naked in the streets. Five patients were described as agitated with three requiring chemical 
and/or physical restraint, and three patients displaying violent, aggressive or assaultive behaviour. In 
one case this led to the use of pepper spray by security personnel with a subsequent severe adverse 
reaction that resulted in the patient’s death (Imam et al, 2013).  
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Effects on physical health 
Of the 17 cases, 9 were reported to show considerable change in vital signs, most often elevated heart 
rate, blood pressure, increased temperature and profuse sweating, symptoms reported to be consistent 
with serotonin syndrome (Boucher et al, 2015). Serotonin syndrome is a potentially life-threatening 
condition involving sudden onset of mental and neurological symptoms caused by an overstimulation 
of serotonergic receptors in the brain (Birmes et al, 2003). In one person the vital signs returned to 
normal after one hour, while several patients improved after 6-12 hours, others after a considerably 
longer time (ranging between several days to several weeks). Three studies did not provide 
information about any physical effects of NPS and one patient had no significant physical symptoms 
due to the drug taken. In addition to directly affecting the vital signs as a result of neurological effects, 
NPS can also seriously disturb kidney and liver function. Six patients showed the signs of renal 
impairment based on increased levels of phosphokinase and/or creatinine (in one case creatinine was 
increased without renal impairment) and two patients subsequently experienced liver function damage 
requiring treatment in intensive care.  
 
Long term effects 
The duration of the effects caused by NPS varied considerably in the case studies. Six patients were 
reported as recovered within 2-12 hours of intoxication or admission. Two persons returned to their 
mental state baseline on day 3 and 4 (consequently). Three patients were still unwell or just improved 
after one month of intoxication. Four studies did not provide detail about the time needed to recover. 
No patients were reported to have long-term kidney or liver damage. 
 
Out of the 17 cases, one death was reported. The authors (Imam et al, 2013) hypothesised that this 
could have been caused by a severe reaction (i.e. respiratory arrest) to the agent in pepper spray used 
to restrain the patient due to the aggressive and violent behaviour. The patient never regained 
consciousness and died several weeks after the incident. 
 
How was NSP use confirmed? 
The case studies generally provided little or no detail about how NPS use was objectively confirmed. 
In most cases NPS use was identified based on self-report (n=9), although two patients denied drug 
use at first and admitted taking drugs only after several weeks of treatment resistance (McClean et al, 
2012) or after repeated hospitalisation (Anderson et al, 2010).  Five patients were reported to have 
been seen taking drugs by clinical staff (Boucher et al, 2015 and Celofiga et al, 2014), in two cases 
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patients were found to be in possession of NPS (Imam et al, 2013 and Smith et al, 2013) and in one 
case the authors did not report any details about how drug use was determined (Imam et al, 2013). 
 
Only 5 of the 12 authors reported having done any testing of the substances used. In seven cases a 
standard urine drug/toxicology screen was performed, usually negative for the NPS taken by the 
patient (Anderson et al, 2010; Boucher et al, 2015; Celofiga et al, 2014; Falgiani et al, 2012; Fröhlich 
et al, 2011; Marques et al, 2013; Thornton et al, 2012; Tully et al, 2011). In 3 cases the substance was 
sent to specialised laboratories for detailed testing (Boucher et al, 2015; Celofiga et al, 2014; Fröhlich 
et al, 2011). Authors of one study reported that poison control was contacted without providing any 
further details (Falgiani et al, 2012) and in four studies no substance testing was reported (Imam et al, 
2013; Khanra et al, 2015; McClean et al, 2012; Smith et al, 2013). 
 
Discussion 
This review aimed to investigate evidence of the effects of NPS for people with serious mental illness.  
Through electronic databases search, of an initial 367 studies, we included 14 studies that met the 
inclusion criteria. Twelve of these were case studies focusing on reporting the acute effects of NPS.    
 
Whilst the substances used by participants varied considerably, the majority experienced significant 
changes in vital signs and often significant and rapid alteration of mental status, involving psychotic 
symptoms and bizarre behaviour. A very common symptom across patients with all diagnoses and 
NPS was violent, assaultive or aggressive behaviour requiring restraint. The particular symptoms 
participants experienced were diverse, ranging from sedation and loss of consciousness, to bizarre 
repeated motions, to erratic running. The wide range of effects was most apparent in a study involving 
four hospitalised patients with schizophrenia who had smoked the same substance but exhibited very 
different symptoms (Celofiga et al, 2014). The authors mentioned that the four patients experiences of 
psychotic symptoms that were not typical of earlier presentations, which may suggest that these were 
“new symptoms” rather than an exacerbation of previous symptoms (Celofiga et al, 2014).  
 
Overall, our findings of the NPS effects are consistent with the effects reported in the general 
population. This may be because we do not yet understand the interaction psychosis, brain 
dysfunction, prescribed medication and NPS. The changes in vital signs, mental status and 
behaviour were also observed in a Japanese retrospective survey of 518 patients (not specific MH 
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patients) brought to emergency department (Kamijo et al 2014) and in a New Zealand overdose 
database analysis (Theron et al, 2007). We did not identify any studies that described positive effects 
of NPS.  
 
We suggest that NPS can have a relatively severe effect on people with psychotic disorders. Although, 
the limited available evidence suggests that the adverse physical health issues resulting from NPS use 
are likely to be similar in both the general population and the SMI population, the effects on mental 
health may differ. For example, one of the common effects of NPS in people with SMI was significant 
behaviour change. Agitation requiring restraint was reported in around a third of the case study 
patients, with one in five being aggressive or violent. For comparison, only 56 (11%) of 518 patients 
brought to emergency departments in Japan for NPS intoxication, demonstrated violent and aggressive 
behaviour to self or others and 24% were irritable or agitated (Kamijo et al, 2014).  Most (96%) of the 
people in the Japanese study recovered completely and did not require any further treatment. Episodes 
of extreme agitation in the general population who have taken NPS may be likely to be solely 
attributed to the use of the drugs, whereas in people with SMI it is possible that levels of behavioural 
disturbance could be viewed by professionals as being part of the SMI diagnosis. In such 
circumstances it is possible that NPS-related aggression in people with SMI might negatively 
influence their future mental health treatment (i.e. in terms of types and doses of prescribed 
medications) or hinder their recovery (i.e. resulting from stigma associated with having a history of 
violent/dangerous behaviour).  
 
It is very likely that the full extent of NPS use by people with SMI is under-recognised and may only 
be reported in the literature when this use results in extremely agitated behaviours and other serious 
health concerns. Due to this, it is also quite possible that there may be people with a SMI diagnosis 
who take NPS and do not come to the attention of health professionals because they may experience 
little harm.  The beliefs of people with SMI that NPS are less harmful than illegal substances or are 
‘natural’ (Every-Palmer, 2011) have also been reported in some studies conducted in the general 
population (Sheridan and Butler, 2010). These ideas may result in people with SMI believing it is 
unnecessary to mention that they have used them during mental health assessments. This issue, 
coupled with the fact that commonly used illicit drug- screening often fails to detect NPS use (Dresen 
et al., 2010), indicates that mental health and other health care professionals should routinely enquire 
about the use of NPS by people with SMI in order to obtain a comprehensive picture of factors 
affecting mental illness.     
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To date, this is the first systematic review of the evidence about the effects of novel psychoactive 
substances on the mental and physical health of people with severe mental illness. The studies 
included in this review provide some indication that for some people with serious mental illness, NPS 
can have potentially serious, effects on both physical and mental health.  
1.7 Review limitations 
This review had several limitations. Firstly, the papers included in this review were mostly case 
studies and a cohort and qualitative studies, which are inherently more likely to be of a lower quality 
and high risk of bias.  Our findings, therefore, might not be applicable for the wider population of 
people with SMI and are not generalizable to the wider population. For practical reasons we excluded 
papers that were not written in English, and this may have resulted in us over-looking some relevant 
material. Reporting in the case studies was also frequently lacking details about patient clinical history 
and long-term follow up, which might not be crucial for the emergency purposes but are necessary for 
a better understanding of NPS effects on people with SMI. One study (Thornton et al, 2012) also 
lacked details about the patient’s psychiatric history and provided no specific diagnosis. Similarly to 
several other reports, the patient’s diagnosis was not independently verified, which seriously limits the 
generalisability of the review findings. 
 
Another limitation is the small number of studies included in the review. Despite the reports of NPS 
use being relatively common among people with severe mental illness (Martinotti et al, 2014), we 
were only able to identify 14 studies focussing on this population. This observation suggests that the 
issue may be under-reported and/or under-researched and more evidence is needed to inform clinical 
decisions and policymaking. It might also indicate reporting bias, i.e. medical professionals selecting 
only severe and clinically interesting cases for publication, rather than reporting all cases of NPS 
intoxication. Due to the small number of studies and included patients, it is also difficult to directly 
compare the prevalence of the NPS effects in people with SMI and the effects within the general 
population published previously. 
 
1.8 Clinical recommendations 
Patients might not always perceive NPS use as “drug use” and may have a lack of knowledge and 
understanding of the likely effects and risks involved in their use. In order to make appropriate 
treatment choices, health professionals need to know what substance the patient had taken. To 
encourage truthful self-report, health professionals should have an understanding of how patients 
perceive NPS in terms of their origin, effects and risks.  
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No studies examined medical and nursing staff knowledge and perceptions of NPS. It is also unclear 
how the different NPS interact with other drugs and medicines used in practice, although some of the 
drug interactions could potentially have serious consequences. When coupled with patients’ reluctance 
to disclose all substance use, health professionals should be particularly vigilant and actively enquire 
about illicit as well as NPS drug use by people with severe mental illness. 
 
1.9 Research recommendations 
Our review suggests that NPS may have serious and potentially lethal consequences for at least some 
people with severe mental illness. However, more research of higher quality is required to provide a 
better understanding of the short and long term effects of NPS. This in turn will aid in detection of use, 
management of intoxication as well as health education regarding effects and risks of such substances. 
The small number of publications about NPS use in the SMI population could potentially be related to 
the health professionals’ lack of knowledge about NPS, but the understanding and attitude of health 
professionals about NPS is largely unknown. Future research should therefore provide more 
information about the ability of health professionals in emergency rooms and psychiatric departments, 
to recognise and address the NPS intoxication by people with SMI. 
 
More observational and prevalence research is needed to provide a better evidence base about the 
effects of NPS on the vulnerable population of people with SMI. It would also be valuable to 
determine whether and to what extent, the effects of NPS differ between people with SMI and people 
without psychiatric illness. Future research could also focus on the entries into medical registers for 
reporting drug use, e.g. Toxbase (www.toxbase.org).   
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Figure 1: Prisma flow diagram of studies in the review 
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Table 1: Characteristics of participants 
 Case studies Questionnaire study Qualitative study 
Participants N=19 (N=17 meeting 
our inclusion criteria) 
N=608 (N=135 had 
psychotic disorders 
and met our inclusion 
criteria) 
N=21 (N=15 
eligible) 
Age Mean=31.3 (SD=7.3) Mean=45 (SD=15) Mean=34 (SD=7.9) 
Gender Male (N=14; 82%) Female (N=322; 53%) 
Head shop drugs used 
by 6.5% of females 
and 19.9% of males. 
Male (N=15; 100%) 
Primary mental health 
diagnosis 
  All treated with 
antipsychotics 
Schizophrenia N=10  N=10 
Bipolar disorder N=6  N=1 
other Diagnosis not 
specified (N=1) 
Psychotic disorders 
(N=23) 
Schizoaffective 
disorders (N=4) 
Substance taken    
Bath salts (not specified) N=5   
Synthetic cathinone ‘NRG-
3’ 
N=1   
Methylenedioxypyrovalerone 
(MDPV) and flephedrone 
N=1   
‘el blanco’1 N=1   
synthetic cannabinoids N=4
2
  N=15
3
 
amphetamine type stimulant 
compounds
4
 
N=1   
Jimson Weed or „Datura 
stramonium“ 
N=1   
Benzylpiperazine (BZP) N=1   
NBOMe
5
 N=1   
Salvia divinorum N=1   
Head shop customers  N=23 (17%)  
1
contains ethylphenidate and benzocaine
 
2
(1-(5-fluoropentyl)-3-(1-naphthoyl) indole (AM-2201) 
3
 synthetic cannabinoid JWH-018
 
4
Butylone - a phenethylamine derivative, and Methylenedioxypyrovalerone - MDPV, a noradrenaline 
and dopamine reuptake inhibitor 
5
NBOMe (25I-NBOMe, 25-CNBOMe and 25H-NBOMe) 
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Table 2: Main characteristics of the included studies 
n Reference Setting and 
design 
NPS  Sample 
size 
Patient 
characteristics 
1 Anderson et 
al. (2015).  
UK, inpatient 
psychiatric 
clinic, case 
study 
‘el blanco’ containing 
ethylphenidate and 
benzocaine; patient drank it 
mixed with cola 
N=1 Age in his 30s, 
male, paranoid 
schizophrenia 
2 Boucher et 
al. (2015).   
 
Intensive care 
unit, case 
study 
NBOMe (25I-NBOMe, 25-
CNBOMe and 25H-NBOMe) 
N=1 Aged 29, 
schizophrenia 
and addiction to 
cannabis 
(occasional) and 
LSD (weaned) 
3 Celofiga et 
al. (2014).  
 
Slovenia, 
intensive 
psychiatric 
unit, case 
study 
synthetic cannabinoid (1-(5-
fluoropentyl)-3-(1-naphthoyl) 
indole (AM-2201). 
N=4 Aged between 
21-35, all 
males, paranoid 
schizophrenia 
(n=2), 
undifferentiated 
schizophrenia 
(n=2) 
4 Falgiani et 
al. (2012).  
USA, ED 
hospital, case 
study 
“Bath salts”  
(Methylenedioxypyrovalerone 
– MDPV- a noradrenaline and 
dopamine reuptake inhibitor) 
N=1 Age 29, female, 
bipolar disorder 
and 
polysubstance 
abuse 
5 Fröhlich et 
al. (2011)  
Ireland, ED 
hospital, case 
study 
amphetamine type stimulant 
compounds (Butylone - a 
phenethylamine derivative, 
and MDVP) 
N=1 Age 28, male, 
bipolar affective 
disorder 
6 Imam et al. 
(2013).   
 
USA, ED 
hospital, case 
series 
“Bath salts” (MDVP) N=3 (3 
eligible 
out of 5) 
Aged 28, 35 
and 39, all 
male, bipolar 
disorder 
7 Khanra et al. 
(2015).  
 
India, 
outpatient 
psychiatric 
department, 
case study 
Jimson Weed or „Datura 
stramonium“ 
N=1 Aged 32, male, 
paranoid 
schizophrenia 
with mental and 
behavioural 
disorders due to 
use of 
hallucinogens 
8 Marques et 
al. (2013).   
 
ED, hospital, 
case study 
Salvia divinorum N=1 Aged 24, 
female, bipolar 
I disorder 
9 McClean et 
al. (2012).  
 
UK, outpatient 
service, case 
study 
“Bath salts” (MDVP) N=1 Aged 29, male, 
schizophrenia 
and past 
polysubstance 
use disorder 
10 Smith et al 
(2013) 
UK, inpatient 
psychiatric 
unit in hospital 
Synthetic cathinone N=1 Aged 45, male, 
paranoid 
schizophrenia 
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and mood 
disorder 
11 Thornton et 
al. (2012).  
USA, ED 
hospital, case 
study 
“Bath salts” (MDVP) N=1 Aged 23, male, 
diagnosis 
unreported 
12 Tully et al. 
(2011).  
 
Ireland, acute 
psychiatric 
unit, case 
study 
Benzylpiperazine (BZP) N=1 Aged 48, male, 
schizophrenia 
Cohort and qualitative studies 
1 Every-
Palmer 
(2011).  
New Zealand, 
forensic and 
rehabilitation 
service, 
interviews 
synthetic cannabinoid JWH-
018 
N=15 (15 
eligible 
out of 21) 
Mean age 34 
(SD=7.9), all 
males, all 
treated with 
antipsychotics. 
Schizophrenia 
(n=10), 
schizoaffective 
(n=4), bipolar 
with psychotic 
feat (n=1) 
2 Lally et al. 
(2013).  
 
Ireland, day 
hospitals, 
questionnaires 
All types N=608 Mean age 45 
(SD=15), 322 
(53%) female, 
135 of all had 
psychotic 
disorders, 23 
(17%) of them 
used head shop 
drugs. Head 
shop drugs used 
by 6.5% of 
females and 
19.9% of males. 
 
Abbreviations: ED (Emergency department in hospital) 
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Table 3: Health and mental health effects of NPS 
n Reference NPS used Patient 
characteristics 
Mental health effects of NPS Physical health 
effects of NPS 
Intervention 
Full research articles   
Case studies   
1 Anderson et 
al. (2015).  
‘el blanco’ 
containing 
ethylphenidate 
and benzocaine; 
patient drank it 
mixed with cola 
Age in his 30s, male, 
paranoid 
schizophrenia (N=1) 
Unable to give any explanation about 
what had happened due to severe 
thought disorder; chaotic and bizarre 
behaviour pattern. On first occasion 
thought disorder lasted for 4 weeks 
and on the second occasion for 10 
days. 
Vital signs normal 
except for pulse 124 
bpm, reduced to 85 
bpm in 1 hour 
Treatment with 
pipotiazine palmitate 
50mg/4 weeks was 
changed to clozapine 
due to incomplete 
recovery and residual 
symptoms of mild 
thought disorder and 
poor insight. The 
patient then stabilised 
enough for a 
discussion and 
education about NPS 
and insight. He was 
discharged 6 months 
after admission, still 
stable at 3 months 
follow-up. 
2 Boucher et 
al. (2015).   
 
NBOMe (25I-
NBOMe, 25-
CNBOMe and 
25H-NBOMe) 
Aged 29, 
schizophrenia and 
addiction to cannabis 
(occasional) and 
LSD (weaned) 
(N=1) 
Patient instilled a drop of a pink 
liquid in the nose and became 
unconscious 1 hour later. One month 
later the patient still had persistent 
memory impairment and significant 
abnormalities in executive functions.
  
Patient suffered partial 
seizure with secondary 
extended 
generalisation, 
bilateral and reactive 
mydriasis, tachycardia 
(120 bpm), 
hypertension (225/70 
mmHg), temperature 
Invasive ventilation in 
the intensive care unit, 
no other intervention 
described 
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39°C, profuse 
sweating (suggesting 
serotonin syndrome). 
Had increased creatine 
kinase without renal 
impairment. 
Encephalopathy 1 
month later. 
3 Celofiga et 
al. (2014).  
 
synthetic 
cannabinoid (1-
(5-fluoropentyl)-
3-(1-naphthoyl) 
indole 
(AM-2201). 
Aged between 21-
35, all males, 
paranoid 
schizophrenia (n=2), 
undifferentiated 
schizophrenia (n=2) 
P1: elevated affect, prominent 
behavioural changes (crawling on 
knees repeating he is a cow), marked 
sedation, narrowed consciousness 
P2: severe agitation and anxiety, 
emergence of paranoid delusions, no 
altered consciousness 
P3: elevated affect (hypomanic), 
severe anxiety and agitation, 
behavioural changes (possible haptic 
hallucinations, whispering to himself 
that he was not free, that his wings 
were cut off) 
P4: agitation, severe formal thought 
symptoms, moderate anxiety, no 
changes in mood or consciousness, 
no positive symptoms 
P1: no physical 
symptoms mentioned 
P2:chest pain, normal 
blood pressure, 
tachycardia (135 
bpm), ECG normal 
P3: increased blood 
pressure (170/120 mm 
Hg), tachycardia (125 
beats per minute) 
P4: tachycardia (140 
beats per minute), 
normal blood pressure 
and ECG 
P1: no additional 
psychopharmacothera
py given; signs of 
intoxication resolved 
in 6 hours 
P2: The dose of oral 
diazepam increased 
to 10 mg 3x a day. 
After 4 hours became 
less anxious, had 
paranoid ideas for 2-3 
hours 
P3: lorazepam 
increased to 2.5 mg 3x 
a day, calmed down 
after 2 hours 
P4:  intramuscular 
lorazepam 2 mg, less 
agitated after 2-3 
hours 
4 Falgiani et 
al. (2012).  
Bath salts Age 29, female, 
bipolar disorder and 
polysubstance abuse 
(N=1) 
Altered mental state (non-
responsive; no further details 
provided), patient was found curled 
up in a corner of a friend's home 
Pulse 85, blood 
pressure 114/79, 
pupils sluggishly 
reactive 
Initial stabilisation 
with normal saline and 
Narcan IV 0.4 mg 
(little response) 
5 Fröhlich et 
al. (2011)  
amphetamine 
type stimulant 
compounds 
Age 28, male, 
bipolar affective 
disorder 
Acute psychosis 
 
Tonic-clonic seizure, 
increased heart rate 
(190 bpm), systolic 
Intubation, cooling, 
mechanical 
ventilation, labetalol 
28 
 
(Butylone - a 
phenethylamine 
derivative, and 
Methylenedioxyp
yrovalerone - 
MDPV) 
(N=1)  
 
  
BP 230 mmHg, 
temperature 39.5° C, 
acute liver failure on 
day 2 post ingestion. 
 
and phenytoin, hepatic 
failure treated 
conservatively 
6 Imam et al. 
(2013).   
 
Bath salts 
(ingested) 
Aged 28, 35 and 39, 
all male, bipolar 
disorder 
(N=5; of them 3 
eligible) 
P1: altered mental status and violent 
behaviour, running naked in the 
streets and through bushes, oriented 
to person, place and time, later got 
confused and agitated. Became 
unresponsive and did not regain 
consciousness 
P4: altered mental status due to bath 
salts overdose 8 hours before; 
agitated, making inappropriate 
comments and oriented to person 
and place only.  
P5: brought to the ED with a police 
escort due to delirious state. Agitated 
with violent behaviour, confused and 
disoriented, not answering questions 
directly.  
P1: blood pressure 
159/105 mm Hg, heart 
rate of 120 bpm, 
normal temperature 
P4: blood pressure 
142/84 mm Hg, heart 
rate 108 bpm, normal 
temperature 
P5: blood pressure 
133/94 mm Hg, heart 
rate104 bpm, normal 
temperature 
P1: pepper sprayed to 
manage aggressive 
behaviour, never 
gained consciousness 
and died after several 
weeks 
P4: Hydrated over 72 
hours and further stay 
uneventful. 
P5: Given intravenous 
fluids for hydration 
and small amount of 
benzodiazepines for 
agitation. Full 
recovery on day 3of 
admission 
7 Khanra et al. 
(2015).  
 
Jimson Weed or 
„Datura 
stramonium“ 
Aged 32, male, 
paranoid 
schizophrenia with 
mental and 
behavioural 
disorders due to use 
of hallucinogens 
(N=1) 
Based on self-report, patient was in a 
state of altered consciousness 
helping him forget his distress, and it 
helped him to get rid of the external 
control on him. NPS used to control 
his motor activity. He had preserved 
affect, delusions of control, 
persecution and reference. 
Derogatory 2nd person auditory 
hallucinations also present. Patient 
denied mental illness but admitted to 
regular NPS use. 
None reported Patient diagnosed with 
schizophrenia and 
mental and 
behavioural disorders 
due to use of 
hallucinogens based 
on ICD-10. Treated 
with haloperidol 20 
mg/day 
29 
 
8 Marques et 
al. (2013).   
 
Salvia 
divinorum 
Aged 24, female, 
bipolar I disorder 
(N=1) 
Psychotic symptoms: auditory 
hallucinations, persecutory and 
religious delusions, all in the absence 
of mood symptoms. Drug screen was 
negative but she reported snorting 
Salvia divinorum in the past month. 
Mild psychotic symptoms were 
already present 2 months before.  
None reported With antipsychotic 
treatment was 
discharged after 33 
days and still stable on 
2 months follow-up. 
9 McClean et 
al. (2012).  
 
Bath salts Aged 29, male, 
schizophrenia and 
past polysubstance 
use disorder (N=1) 
Psychotic symptoms, tangential 
thought process, disorganised speech 
and behaviour. Auditory 
hallucinations and paranoid 
delusions. Erratic behaviours 
seemingly consistent with a relapse 
of methamphetamine use (denied by 
patient). Psychotic symptoms 
persisted for 4 weeks despite 
olanzapine treatment. Patient 
described the effects of bath salts as 
‘exactly the same as meth’ but 
cheaper. The euphoria took effect 
immediately, lasting for 4-5 hours. 
Decrease in appetite, 
no other physical 
symptoms reported 
Olanzapine 20 mg/day 
increased to 40 
mg/day, then 
intramuscular 
Risperdal Consta 50 
mg every 2 weeks and 
oral risperidone 4 
mg/day 
10 Smith et al 
(2013) 
Synthetic 
cathinone 
Aged 45, male, 
paranoid 
schizophrenia and 
mood disorder 
Increasing agitation (during a 6 
month long hospitalisation), no 
further details provided 
Sinus tachycardia, an 
apparent dislocation of 
a thumb and 
echymoses on both 
knees from a fall; 
hyperkalaemia 6.3 
mol/L, hyponatraemia 
of 129 mmol/L, life-
threatening acute 
kidney failure with 
creatine of 1032 
μmol/L; 
Intensive care unit, 
aggressive fluid 
regime and 
monitoring, treated 
under the Mental 
Capacity Act, 
antipsychotics stopped 
pending review of 
renal and hepatic 
function, which 
improved with 
treatment. 
11 Thornton et Bath salts Aged 23, male, Bizarre behaviour, suicidality, blood pressure 133/68 Due to agitation he 
30 
 
al. (2012).  diagnosis unreported 
(N=1) 
hallucinations after insufflating a 
bath salt. Patient was agitated, had 
visual, tactile and auditory 
hallucinations. No evidence of 
trauma.  
mmHg; heart rate 109 
bpm; temperature 
36.9°C, diaphoretic 
and tachycardic with 
mydriasis 
was physically and 
chemically restrained. 
At awakening after 5 
hours, he was no 
longer hallucinating or 
suicidal. 
12 Tully et al. 
(2011).  
 
Benzylpiperazine 
(BZP) 
Aged 48, male, 
schizophrenia (N=1) 
Taxi driver reported the patient nor 
responding to questions, murmuring 
to himself incoherently, engaged in 
repetitive movements. Staff in 
hospital described him as irritable, 
unable to concentrate on simple 
activities, incoherent when 
answering questions about his 
mental state or general topics.  
No abnormal 
cardiovascular, 
respiratory or 
gastrointestinal 
findings; marked 
myoclonic jerking in 
all limbs 
Treated with 
olanzapine and by the 
fourth day he returned 
to his baseline level of 
functioning. 
Cohort and qualitative studies   
1 Every-
Palmer 
(2011).  
synthetic 
cannabinoid 
JWH-018 
Total N=15 (15 
eligible out of 21) 
Mean age 34 
(SD=7.9), all males, 
all treated with 
antipsychotics. 
Schizophrenia 
(n=10), 
schizoaffective 
(n=4), bipolar with 
psychotic feat (n=1) 
Anxiety and psychotic symptoms 
commonly reported; 69% of users 
experiencing symptoms consistent 
with psychotic relapse after smoking 
the drug. Nobody reported becoming 
physically unwell after using it. 
Three people reported developing 
tolerance but no one had withdrawal 
symptoms. 
  
2 Lally et al. 
(2013).  
 
Any type of NPS 
participants self-
reported to have 
used 
Total N=608) 
Mean age 45 
(SD=15), 322 (53%) 
female, 135 of all 
had psychotic 
disorders, 23 (17%) 
of them used head 
shop drugs. Head 
Total of 41 (54%) of individuals 
reported deleterious effect of head 
shop products on mental health. 
Most commonly, people with 
psychosis had exacerbation or 
development of psychotic symptoms 
(65%). All in-patients with psychosis 
reported deleterious effects and 
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shop drugs used by 
6.5% of females and 
19.9% of males. 
worsening of psychosis (67%) after 
ingesting head shop drugs. 
 
